Hemorrhoids - Pipeline Insight, 2025

This “Hemorrhoids - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hemorrhoids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Hemorrhoids: Understanding

Hemorrhoids: Overview

Hemorrhoids, also known as piles, are swollen blood vessels located in the lower rectum and anus. They are a common condition that can cause discomfort and various symptoms, ranging from mild itching to rectal bleeding. Hemorrhoids can be classified into internal and external types based on their location relative to the dentate line. Internal hemorrhoids are painless and occur above the dentate line, while external hemorrhoids, below the dentate line, can be painful when swollen. The prevalence of hemorrhoids increases with age, peaking in individuals aged 45-65 years. Despite being a common condition, many individuals may feel embarrassed seeking treatment for hemorrhoids. Treatment options include conservative measures like dietary modifications, fiber supplementation, and topical treatments, as well as surgical interventions for more severe cases.

Hemorrhoids are caused by excessive pressure on the veins in the lower rectum and anus, leading to swelling and inflammation. This pressure can result from various factors, including straining during bowel movements, sitting on the toilet for long periods, chronic constipation or diarrhea, a low-fiber diet, weakening of the supporting tissues in the anus and rectum, and frequently lifting heavy objects. Additionally, pregnancy, aging, and certain medical conditions can also contribute to the development of hemorrhoids. The increased pressure can cause the veins to stretch and bulge, leading to symptoms such as bleeding, itching, discomfort, and pain. Understanding the causes of hemorrhoids is essential for effective prevention and treatment strategies.

Hemorrhoids can manifest with various signs and symptoms, including painless bleeding from the anal area, anal itching, pain in the anal region, swelling, and feeling a lump in the anus. External hemorrhoids may also cause extreme itching around the anus, uncomfortable lumps, and discomfort. In some cases, hemorrhoids can lead to the formation of blood clots, resulting in severe pain, swelling, inflammation, and the presence of hard, discolored lumps near the anus.

Hemorrhoids are diagnosed through a physical examination, including a digital rectal exam and potentially additional tests like anoscopy, sigmoidoscopy, or colonoscopy to confirm the diagnosis and rule out other conditions. Initial treatment focuses on lifestyle modifications like increasing fiber intake, staying hydrated, and using over-the-counter topical creams or suppositories to relieve symptoms.

'Hemorrhoids - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemorrhoids pipeline landscape is provided which includes the disease overview and Hemorrhoids treatment guidelines. The assessment part of the report embraces, in depth Hemorrhoids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemorrhoids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hemorrhoids R&D. The therapies under development are focused on novel approaches to treat/improve Hemorrhoids.

Hemorrhoids Emerging Drugs Chapters

This segment of the Hemorrhoids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemorrhoids Emerging Drugs

CITI-002: Citius Pharmaceuticals

CITI-002 is a proprietary topical formulation intended to provide symptomatic relief to individuals suffering from hemorrhoids. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Hemorrhoids.

Hemorrhoids: Therapeutic Assessment

This segment of the report provides insights about the different Hemorrhoids drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hemorrhoids

There are approx. 3+ key companies which are developing the therapies for Hemorrhoids. The companies which have their Hemorrhoids drug candidates in the most advanced stage, i.e. Phase II include, Citius Pharmaceuticals.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hemorrhoids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemorrhoids: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemorrhoids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemorrhoids drugs.

Hemorrhoids Report Insights

• Hemorrhoids Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hemorrhoids Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hemorrhoids drugs?
• How many Hemorrhoids drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemorrhoids?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hemorrhoids therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hemorrhoids and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Citius Pharmaceuticals
• Edesa Biotech

Key Products

• CITI-002
• EB02

This product will be delivered within 2 business days.